Skip web photoSkip Fleshman


Skip Fleshman is a Managing Partner at Asset Management Ventures (AMV). AMV is a Palo Alto based, early-stage venture capital firm that was founded in 1965. They focus on investing in digital health, therapeutics, mobile and data analytics companies. Skip is an advisor to Stanford’s StartX, Rock Health and Boston Children’s Hospital. He is actively investing in startups focused on digital health, mobile and big data and his current investments include: HealthTap, Reify Health, Evidation Health, Benefitter, Lark, Morpheus Medical, Welkin Health, Ooma, Skybox Imaging, Kii, LiquidM, RallyPoint and Icon Aircraft.


Skip will be one of the distinguished speakers at the 7th Semi-Annual Life Science Financial Forum.


How do you believe the evolving healthcare landscape has affected product pricing and value discussions?
The ACA has completely changed financial incentives and shifted how the money flows in healthcare. More and more we are shifting away from fee-for-service and into different business models that force population health management. Early signs of this are bundled payments, centers of excellence, and readmission penalties. Employers are increasing shifting to high deductible plans that force their employees to share in costs – making them more cost sensitive.